Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate®

Our lead product candidate

Pipeline

General Corporate presentation

Press Releases

September 6, 2024

Egetis highlights seven abstracts related to MCT8 deficiency, and two abstracts related to tiratricol and RTH-beta, published ahead of the Annual Meeting of the European Thyroid Association

Read more

August 28, 2024

New post-hoc analysis reports effects of tiratricol on patient-centered outcome measures in patients with MCT8 deficiency

Read more

Regulatory

August 22, 2024

Interim report Q2 2024

Read more

Upcoming event

September 19, 2024

Pareto Annual Healthcare Conference

Latest presentation

June 20, 2024

Replay of Triac Trial II topline results webcast

Latest Report

August 22, 2024

Interim report Q2 2024

Calendar and upcoming reports

September 19, 2024

Pareto Annual Healthcare Conference

November 8, 2024

Interim Report Q3 2024 (7:00am CET)

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]